Compared with the use of SGLT2 inhibitors, the use of GLP-1 receptor agonists and DPP-4 inhibitors was associated with a similar risk for acute pancreatitis (hazard ratio [HR], 1.01; 95% CI, 0.90-1.13 ...

Biliary atresia (BA) represents one of the leading causes of pediatric liver failure, often requiring surgical intervention or transplantation in early infancy. Although traditionally viewed as an ...

Biliary hyperkinesia is an emerging functional gallbladder disorder characterized by elevated gallbladder ejection fraction and right upper quadrant pain in the absence of gallstones. This case study ...

Neonatal hepatitis (NH) and biliary atresia are two separate conditions that share specific symptoms. Both conditions affect newborn infants and can cause liver damage. Bile is a substance the liver ...

Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...

Previous clinical studies have indicated reduced circulating mucosal-associated invariant T (MAIT) cells in individuals with coronary artery disease. However, the precise role and underlying ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements. In the treatment of newly diagnosed biliary tract cancer, the current standard ...

Please provide your email address to receive an email when new articles are posted on . Healio spoke with Ahmad Anouti, MD, about a presentation at The Liver Meeting on the prognostic value of ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Credit: Jazz Pharmaceuticals Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor. Findings showed the ORR was 52% (95% CI, 39-65), of which ...

Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug for the treatment of a type of biliary tract cancer, the company said on Wednesday.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer. The FDA granted an accelerated ...